GT Biopharma (OXIS) Breaks To New Highs!
We have continued to keep a very close eye on our newest corporate focus, GT Biopharma (OXIS). It tested previous highs earlier this week and today it broke to new highs of $0.048! At the time of this email being written, (OXIS) continues to test this level and could be set to break out again. Momentum has been picking up a lot this afternoon and with more than an hour left, it woudn’t surprise us if this was just a “warm-up”.
Ahead of their corporate conference call slated for next Wednesday (8-16), the buzz has been building around its latest proposed acquisition of Georgetown Translational Pharmaceuticals Inc. and what it could bring to the table for (OXIS). On top of this, (OXIS) has also recently announced the addition of new patients to the company’s Phase 2 FDA trials. GT Biopharma (OXIS) tested previous highs earlier this week and yesterday (8-10) it broke above $0.04. (OXIS) remains up about 50% higher than when we first began re-visiting this previous 400% runner.
In our opinion (OXIS) could be just getting started here. Ahead of this proposed merger and ahead of this next presentation at the Rodman & Renshaw Conference in New York, attention has been building so much so that now (OXIS) is holding at levels of more than 50% compared to where it was just a few weeks ago.
With the anticipation of this acquisition building, there also comes new leadership with a strong team of experienced members. For example, the new CEO, Dr. Clarence-Smith co-founded Chase Pharmaceuticals Corporation in Washington D.C. and served as Chairman of the company’s Board from 2008 to 2014. Chase Pharmaceuticals was acquired by Allergan, PLC in 2016 in a deal that, with milestones, could reach $1 billion.
Dr. Clarence-Smith also held executive management positions with Sanofi, Roche, Otsuka Pharmaceutical and Prestwick Scientific Capital. She is co-founder and a managing member of KM Pharmaceutical Consulting in Washington, D.C.
Additionally, GT Biopharma, Inc’s management team will be joined by a new Chief Medical Officer (CMO) formerly Vice President and Chief Medical Officer and Medical Director of Oncology Clinical R&D of Pfizer, Inc. (PFE), according to the company.
If you have not done so, take a close look at (OXIS) because this could be just the beginning of the next move for a previous 400% biotech runner. CLICK NOW TO DOWNLOAD FULL REPORT
GET ALERTS FASTER!
TEXT “BIOTECH” TO 474747 NOW!